AMD

Ophthalmologists weigh in on how the extended-duration therapy may reduce treatment burden for patients with wet age-related macular degeneration.

Harpal Sandhu, MD, FRCSC, discusses the preclinical performance of XPK-640 and how Optigo’s hyaluronic acid-anchoring platform may reshape dosing expectations in retinal disease.

The trial is evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).

The trial will be evaluating AXPAXLI dosed every 6 months versus aflibercept (2 mg) dosed every 8 weeks in treatment-naïve wet AMD patients.

This acquisition will include Adverum’s lead candidate, Ixo-vec, a gene therapy treatment for wet AMD.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

AMD treatment may become unrecognizable as gene therapies evolve.

EYDENZELT is Celltrion's first FDA-approved biologic product in ophthalmology.

Sura-vec is intended to be a potential 1-time treatment consisting of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF).

Holz discusses advancements in retinal disease treatments at the EURETINA meeting, featuring gene therapy and innovative implants to enhance patient care.

Patricio Schlottmann highlights promising long-term results of faricimab for wet AMD, showcasing sustained visual gains and excellent safety in patients.

Miere discusses retinal studies on AMD and vein occlusion, highlighting imaging advancements and the future of machine learning in treatment predictions.

This new technology, the MacuMira system, is a non-invasive treatment now available in more than 150 clinics across Canada.

In honor of looking back at 50 years, we look forward at a world where the toughest eye diseases could be cured in the blink of an eye.

EYLUXVI (ALT-L9) is an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.

Character Biosciences enhances its leadership team and secures $93 million in Series B funding to advance treatments for degenerative eye diseases.

Guymer discusses early intervention strategies for intermediate AMD, highlighting risk factors, and potential trial designs to prevent vision loss.

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment.

The company’s lead clinical-stage program, OLN324, is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody currently in phase 1b clinical development for patients with either wAMD or DME.

The presence of AMD predicted an increased risk of all-cause and CVD mortality in patients with a high risk of CVD, even in the early stages of AMD.

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.